TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29288995

Group type: EXPERIMENTAL
Intervention: #Tamojunto prevention program
Number of subjects: 6637

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6637
Study: 28747206

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Vaginal sacrospinous fixation
Number of subjects: 106
Study: 25500202

Group type: EXPERIMENTAL
Intervention: 10 g inulin-propionate ester
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 g/day inulin-propionate ester supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: inulin-control group
Number of subjects: 60
Study: 23363981

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (no probucol treatment)
Number of subjects: 162
Study: 21942491

Group type: EXPERIMENTAL
Intervention: Pre-training evaluation and feedback (E&F group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 40
Study: 18436353

Group type: EXPERIMENTAL
Intervention: Intradermal immunization (0.1 ml of trivalent influenza vaccine)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intradermal immunization
Number of subjects: 34

Group type: COMPARATOR
Intervention: Subcutaneous immunization (0.1 ml of trivalent influenza vaccine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Subcutaneous immunization
Number of subjects: 34
Study: 16520199

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional exposure
Number of subjects: 41
Study: 14510756

Group type: EXPERIMENTAL
Intervention: Ionic low osmolar agent
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Non-ionic, iso-osmotic agent
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Non-ionic, low osmolar agent
Number of subjects: 37

Group type: COMPARATOR
Intervention: Diagnostic angiography
Number of subjects: 37

Group type: COMPARATOR
Intervention: Coronary intervention
Number of subjects: 37
Study: 11938857

Group type: EXPERIMENTAL
Intervention: Olium Psidium guajava (PG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Gegen Qinlian decoction (Control)
Number of subjects: 62
Study: 9351034

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 78
Study: 8409106

Group type: EXPERIMENTAL
Intervention: American Heart Association (AHA) diet
Number of subjects: 3401

Group type: EXPERIMENTAL
Intervention: AHA diet
Number of subjects: 3401

Group type: EXPERIMENTAL
Intervention: High-fiber AHA-type diet
Number of subjects: 3401
Study: 3083851

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (350 mg intravenously)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sodium salicylate (1200 mg daily for 3 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (60.7 mg kg‐1 for 8 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sodium salicylate (52.6 mg kg‐1 for 8 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 13
Study: 29898752

Group type: EXPERIMENTAL
Intervention: Trastuzumab and chemotherapy (Arms B and C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chemotherapy only (Arm A)
Number of subjects: 50
Study: 28115966

Group type: EXPERIMENTAL
Intervention: Walnut oil (15 g/day for three months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 24300222

Group type: EXPERIMENTAL
Intervention: Factsheet about pain management (with pretest)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Factsheet about pain management (without pretest)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (without pretest)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (with pretest)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 120
Study: 21958929

Group type: COMPARATOR
Intervention: Bag-valve-mask (BVM)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pressure-limited, flow adaptive ventilator (MEDUMAT Easy CPR)
Number of subjects: 74
Study: 21265206

Group type: EXPERIMENTAL
Intervention: Hook needle knife treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local-blocking (control)
Number of subjects: 60
Study: 17935553

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15736119

Group type: EXPERIMENTAL
Intervention: Low rate of insulin infusion (1.5 mU insulin/kg per minute)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High rate of insulin infusion (15 mU insulin/kg per minute)
Number of subjects: 30
Study: 12137603

Group type: EXPERIMENTAL
Intervention: ACEI group (benazepril 10 mg/d)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Non-ACEI group (control)
Number of subjects: 131
Study: 9450772

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Modafinil (both dosages)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 7609520

Group type: EXPERIMENTAL
Intervention: Tumour excision plus continuous tamoxifen
Number of subjects: 77

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 77
Study: 2550045

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perindoprilat (2 mg intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg oral) and Perindoprilat (2 mg intravenously)
Number of subjects: 0
Study: 4608503

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) therapy
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (not receiving SK)
Number of subjects: 2000
Study: 30985244

Group type: EXPERIMENTAL
Intervention: PPIC 2.1 survey administered to beneficiaries
Number of subjects: 12364

Group type: EXPERIMENTAL
Intervention: PPIC 2.1 survey
Number of subjects: 12364
Study: 31052322

Group type: EXPERIMENTAL
Intervention: Red Bull beverage (RB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study: 29717841

Group type: EXPERIMENTAL
Intervention: Triple acupuncture at the Qugu acupoint (twice a week for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Levofloxacin Mesylate Tablets (0.5 g, tid) + Terazosin Hydrochloride Capsules (2 mg qd) for 4 weeks
Number of subjects: 90
Study: 25481694

Group type: EXPERIMENTAL
Intervention: Muscular endurance and resisted strengthening protocols
Number of subjects: 79

Group type: COMPARATOR
Intervention: Routine activity maintenance (Control)
Number of subjects: 79
Study: 24636286

Group type: EXPERIMENTAL
Intervention: ETV
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: ETV maleate
Number of subjects: 218
Study: 21682910

Group type: EXPERIMENTAL
Intervention: Goal-based intervention including telephone contacts, written information provision, home visitation, and contact with treating health professionals.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 0
Study: 18413983

Group type: EXPERIMENTAL
Intervention: Venous thromboembolism prophylaxis (mechanical, pharmacological, or a combination of both)
Number of subjects: 0
Study: 16797994

Group type: EXPERIMENTAL
Intervention: Mobile bearing UKA (Oxford)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed bearing UKA (Miller/Galante)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 15008339

Group type: EXPERIMENTAL
Intervention: Vitremer (resin-modified glass ionomer)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dyract (polyacid-modified resin)
Number of subjects: 12
Study: 10753731

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9064671

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no n-3 fatty acids)
Number of subjects: 32
Study: 1612952

Group type: EXPERIMENTAL
Intervention: Hypothalamic‐pituitary radiation therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (nonirradiated)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 47
Study: 6145533

Group type: EXPERIMENTAL
Intervention: Prenalterol (1 mg/hr)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prenalterol (2 mg/hr)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (300 micrograms/hr)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (600 micrograms/hr)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Salbutamol (low dose)
Number of subjects: 7
Study: 30678710

Group type: EXPERIMENTAL
Intervention: Outpatient follow-up from the patient's home using telemedicine (teleSCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (hospital outpatient follow-up)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine (teleSCI)
Number of subjects: 0
Study: 29957706

Group type: EXPERIMENTAL
Intervention: Phenotype 1 (lower plasma concentrations of TNF-α, IL-6, IL-8)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Phenotype 2 (higher plasma concentrations of TNF-α, IL-6, IL-8)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: High PEEP in Phenotype 1
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Low PEEP in Phenotype 1
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: High PEEP in Phenotype 2
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Low PEEP in Phenotype 2
Number of subjects: 242
Study: 27173380

Group type: EXPERIMENTAL
Intervention: Challenging diet (CD) with 10% proteins/45% lipids/45% carbohydrates (fat on sugar ratio = 1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Basal diet (BD) with 10% proteins/30% lipids/60% carbohydrates (fat on sugar ratio = 0.5)
Number of subjects: 34
Study: 25375154

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 529

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 529
Study: 23147138

Group type: EXPERIMENTAL
Intervention: Two doses of RIX4414 vaccine (n = 328)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo (n = 325)
Number of subjects: 653
Study: 21056809

Group type: EXPERIMENTAL
Intervention: Propofol at 1 μg/mL
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propofol at 2 μg/mL
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propofol at 3 μg/mL
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propofol at 4 μg/mL
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propofol at 5 μg/mL
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propofol at 6 μg/mL
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 122
Study: 17163285

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 50 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Ketoprofen 100 mg
Number of subjects: 252
Study: 14570662

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion (30 microg/h)
Number of subjects: 48

Group type: COMPARATOR
Intervention: IV fentanyl infusion (30 microg/h)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 48
Study: 11115439

Group type: EXPERIMENTAL
Intervention: 0.1N hydrochloric acid (HCl) perfusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline solution perfusion
Number of subjects: 7
Study: 9175684

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in pre-eclampsia group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in uncomplicated pregnancy group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-1ra predictive values at gestational weeks 20-25
Number of subjects: 30
Study: 1564652

Group type: EXPERIMENTAL
Intervention: 3M multifocal IOL
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional monofocal implant
Number of subjects: 77
Study: 3890786

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy alone (32 patients)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus BCG vaccine (24 patients)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Ten-day chemotherapy (vincristine sulfate, cytarabine, prednisone)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Five-day chemotherapy (cytarabine)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall survival in evaluable patients with acute myelogenous leukemia
Number of subjects: 216
Study: 30831300

Group type: EXPERIMENTAL
Intervention: Diagnostic transforaminal epidural injection (DTEI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no DTEI)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DTEI
Number of subjects: 99
Study: 29229342

Group type: EXPERIMENTAL
Intervention: Parahippocampectomy (PHC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Selective amygdalohippocampectomy (SAH)
Number of subjects: 43
Study: 26956611

Group type: EXPERIMENTAL
Intervention: 10 g LNS/d
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 20 g LNS/d
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 40 g LNS/d
Number of subjects: 1932
Study: 24481578

Group type: EXPERIMENTAL
Intervention: Subcutaneously implanted epidural ports (SIEP) with morphine administration (starting with 2 mg, maximum 4 mg per day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Subcutaneously implanted epidural ports (SIEP) with morphine administration
Number of subjects: 21
Study: 22627883

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FEIBA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FEIBA (lower doses)
Number of subjects: 10
Study: 20167582

Group type: EXPERIMENTAL
Intervention: win with the chin analogy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: anatomic instructions
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: sniffing position analogy
Number of subjects: 81

Group type: COMPARATOR
Intervention: no instructions (control)
Number of subjects: 81
Study: 17056272

Group type: EXPERIMENTAL
Intervention: Cuban recombinant hepatitis B vaccine (Heberbiovac HB), 20 microg HBsAg/mL, administered in three doses at month 0, 1, and 2.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (older production facilities).
Number of subjects: 501
Study: 17134634

Group type: EXPERIMENTAL
Intervention: ICD therapy in white patients
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: ICD therapy in black patients
Number of subjects: 1232
Study: 12565987

Group type: COMPARATOR
Intervention: 5-FU 60 mg/kg as a continuous infusion over 48 h, with methotrexate 40 mg/m(2) administered just before 5-FU (control regimen)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: PALA 250 mg/m(2) as a 15 min infusion administered 24 h before 5-FU and methotrexate
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 198
Study: 10926589

Group type: EXPERIMENTAL
Intervention: Counselling sessions (7 sessions over 3 months)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 108
Study: 8831323

Group type: EXPERIMENTAL
Intervention: One postoperative visit (Group A, n = 48)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Two postoperative visits (Group B, n = 48)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Three postoperative visits (Group C, n = 48)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 144
Study: 1328817

Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/d for 4 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Olive oil (15 g/d for 4 weeks)
Number of subjects: 32
Study: 4062571

Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, p.m. dose at different times
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, p.m. dose 30 minutes before evening meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, p.m. dose mid-afternoon
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, all treatment periods
Number of subjects: 15
Study: 30081930

Group type: EXPERIMENTAL
Intervention: SPARC implementation intervention (EHR decision support, performance monitoring and feedback, front-line support from external practice coaches)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pre-implementation period
Number of subjects: 22
Study: 27780335

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 91
Study: 23588485

Group type: EXPERIMENTAL
Intervention: Self-administered PNF hamstring stretching 2 × 40 seconds on each leg for 6 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Static stretching 2 × 40 seconds on each leg for 6 weeks
Number of subjects: 19
Study: 21743415

Group type: EXPERIMENTAL
Intervention: Capsaicin rinse (0.02%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 23
Study: 20464808

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy for pregnant substance users (MET‐PS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 200
Study: 17709169

Group type: EXPERIMENTAL
Intervention: PSA testing and biopsy acceptance
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PSA testing
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Non-responders to PSA testing
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Biopsy refusal
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: General perceptions
Number of subjects: 58
Study: 15986592

Group type: EXPERIMENTAL
Intervention: Computer-aided image analysis for microvessel density
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual counting method for microvessel density
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for overall survival estimation
Number of subjects: 50
Study: 11807436

Group type: EXPERIMENTAL
Intervention: Methotrexate strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rotational strategy of modified cyclosporine and methotrexate
Number of subjects: 0
Study: 10703890

Group type: EXPERIMENTAL
Intervention: Combination therapy (verapamil 180 mg plus trandolapril 2 mg)
Number of subjects: 898

Group type: COMPARATOR
Intervention: Monotherapy (dose-titration or switching to a different drug class)
Number of subjects: 898
Study: 8732126

Group type: EXPERIMENTAL
Intervention: Shuxuening tablet No. 1 (crude extract)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Shuxuening tablet No. 2 (pure extract)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Shuxuening tablet No. 1 and No. 2
Number of subjects: 46
Study: 1748495

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms twice daily for 4 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo tablets twice daily for 4 weeks
Number of subjects: 37
Study: 7140487

Group type: COMPARATOR
Intervention: Chenodeoxycholic (chenic) acid, 15 mg/kg/day, administered in three divided doses at mealtimes with an unrestricted diet (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bedtime administration of chenodeoxycholic (chenic) acid, 15 mg/kg/day, with a low cholesterol diet (Group B)
Number of subjects: 48
Study: 30228368

Group type: EXPERIMENTAL
Intervention: Local anaesthetic infiltration with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 23
Study: 28072552

Group type: EXPERIMENTAL
Intervention: Dextenza (sustained-release dexamethasone intracanalicular insert)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Vehicle (PV)
Number of subjects: 59
Study: 24509880

Group type: EXPERIMENTAL
Intervention: Rotating-platform TKA
Number of subjects: 331

Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 331
Study: 23306328

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 21697538

Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable/Berry (FVB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 19413207

Group type: EXPERIMENTAL
Intervention: Rapid malaria dipstick test (RDT)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Microscopy (Giemsa-stained thick and thin blood smears)
Number of subjects: 515
Study: 16813177

Group type: EXPERIMENTAL
Intervention: Needle-picking therapy at bilateral Shengzhi points, Dicong Shenjing points and L2 Shenjing points
Number of subjects: 168

Group type: COMPARATOR
Intervention: Oral administration of Wuzi Yanzong Pills
Number of subjects: 168
Study: 12635531

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol (remifentanil 0.4 microgram/kg and propofol 1 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol (alfentanil 20 micrograms/kg and propofol 1 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol
Number of subjects: 60
Study: 10720025

Group type: EXPERIMENTAL
Intervention: GH therapy (starting dose, 10 microg/kg x day, final dose 4 microg/kg x day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study: 9161742

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1 i.v. before induction of anaesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 1547055

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20